Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | FGFR2 |
Variant | V564F |
Impact List | missense |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | FGFR2 V564F (also referred to as V565F from the FGFR2IIIb isoform) lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). V564F is predicted to confer a gain of function as demonstrated by increased Fgfr2 kinase activity in cell culture (PMID: 25169980), and has been shown to be associated with secondary resistance to FGFR inhibitors (PMID: 28034880). |
Associated Drug Resistance | Y |
Category Variants Paths |
FGFR2 mutant FGFR2 act mut FGFR2 V564F |
Transcript | NM_000141.4 |
gDNA | chr10:g.121496705C>A |
cDNA | c.1690G>T |
Protein | p.V564F |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_000141 | chr10:g.121496705C>A | c.1690G>T | p.V564F | RefSeq | GRCh38/hg38 |
NM_000141.4 | chr10:g.121496705C>A | c.1690G>T | p.V564F | RefSeq | GRCh38/hg38 |
XM_024447887.1 | chr10:g.121488075_121488077delGTAinsTTT | c.1690_1692delGTAinsTTT | p.V564F | RefSeq | GRCh38/hg38 |
NM_001144916 | chr10:g.121487374_121487376delTACinsAAA | c.1690_1692delGTAinsTTT | p.V564F | RefSeq | GRCh38/hg38 |
NM_001144916.1 | chr10:g.121487374_121487376delGTAinsTTT | c.1690_1692delGTAinsTTT | p.V564F | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 V564F | Advanced Solid Tumor | resistant | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing FGFR2 V564F were resistant to Truseltiq (infigratinib) in culture (PMID: 25349422). | 25349422 |
FGFR2 V564F | Advanced Solid Tumor | resistant | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells over expressing FGFR2 V564F were resistant to Truseltiq (infigratinib) in culture (PMID: 28034880). | 28034880 |
FGFR2 V564F | Advanced Solid Tumor | sensitive | Debio 1347 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Debio 1347 inhibited proliferation of transformed cells over expressing FGFR2 V564F in culture and inhibited tumor growth in cell line xenograft models (PMID: 25169980). | 25169980 |
FGFR2 V564F | Advanced Solid Tumor | resistant | AZD4547 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, transformed cells over expressing FGFR2 V564F were resistant to AZD4547 in culture and in cell line xenograft models (PMID: 25169980). | 25169980 |